OCULAR THERAPEUTIX,INC. (NASDAQ:OCUL) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k

6 years ago

OCULAR THERAPEUTIX,INC. (NASDAQ:OCUL) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07

Submission of Matters to a Vote of Security Holders.

Ocular Therapeutix held its Annual Meeting of Stockholders on June14, 2018. The following is a summary of the matters voted on at that meeting.

(a)

Ocular Therapeutix’s stockholders elected Antony Mattessich, W. James O’Shea and Charles Warden as ClassI directors to serve until the 2021 Annual Meeting of Stockholders, each such director to hold office until his successor has been duly elected and qualified. The results of the stockholders’ vote with respect to the election of such ClassI directors were as follows:

Name	VotesFor	Votes Withheld	Broker Non-Votes
Antony Mattessich	15,588,755	3,217,038	14,553,989
W. James O’Shea	14,447,012	4,358,781	14,553,989
Charles Warden	14,949,006	3,856,787	14,553,989

(b)

Ocular Therapeutix’s stockholders ratified the selection of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December31, 2018. The result of the stockholders’ vote with respect to such ratification were as follows:

For	Against	Abstain	BrokerNon-Votes
32,785,789	286,003	287,990

About OCULAR THERAPEUTIX,INC. (NASDAQ:OCUL)
Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Company’s product pipeline includes marketed candidate ReSure Sealant and products under development, such as OTX-DP, OTX-TP, OTX-MP and anti-VEGF hydrogel depot. The Company’s lead product candidates are OTX-DP and OTX-TP. The OTX-DP product candidate incorporates the corticosteroid dexamethasone as an active pharmaceutical ingredient in its punctum plug. The OTX-TP product candidate incorporates the prostaglandin analog travoprost as an active pharmaceutical ingredient in its punctum plug.